ReviewInvestigational new drugs2003
Use of positron emission tomography in anticancer drug development.
Review in Investigational new drugs, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Feasibility of [European journal of nuclear medicine and molecular imaging · 2023Article
- [European journal of nuclear medicine and molecular imaging · 2020Article
- Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future.Molecular imaging and biology · 2012Review
- Medical imaging in new drug clinical development.Journal of thoracic disease · 2010Article
- Molecular imaging as a tool for translating breast cancer science.Breast cancer research : BCR · 2008Review
- Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy.Academic radiology · 2007Review
- Current and future use of positron emission tomography (PET) in breast cancer.Journal of mammary gland biology and neoplasia · 2006Review
- Positron emission tomography imaging of small animals in anticancer drug development.Molecular imaging and biologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Positron emission tomography (PET) is increasingly being used in anticancer drug development. The technique is applicable to studies of drug delivery, and where specific probes are available, to provide pharmacodynamic readouts noninvasively in patients. Mathematical modeling of the imaging data enhances the quality of information that is obtained from such studies. This section provides a review of the PET methodologies that have been used for the development of new cancer therapies. Other than imaging of radiolabeled drugs, PET modeling has found extensive application in studies with 2-[11C]thymidine, [18F]fluorodeoxyglucose, H2(15)O, C15O, and receptor ligands.
Indexed as
Identifiers
12889738What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.